Paris—Dentons Paris advised Bpifrance Large Venture on the Series A funding of Aqemia.

Aqemia is a Paris-based deeptech founded in 2019 and specialised in drug discovery by combining quantum physics and artificial intelligence.

The €30 million Series A funding round was co-led by Eurazeo and Bpifrance, through its Large Venture fund, with the participation of Elaia, its historic investor.

This financing will further support Aqemia's core mission: to massively advance drug discovery through a first-class technology platform combining quantum-inspired physics and artificial intelligence.

Our multidisciplinary Paris team included:

• On corporate and contractual aspects: Olivia Guéguen (partner), Laura Godard, Pierre-Marie Gallo, Nouçayba Soltani and Marie Tavernier (associates)
• Employment law: Katell Déniel-Allioux (partner) and Julie Ragueneau (counsel)
• Intellectual property: Loïc Lemercier (partner) and Tom Blanchet (associate)

About Dentons

Dentons is designed to be different. As the world's largest global law firm with 21,000 professionals in over 200 locations in more than 80 countries, we can help you grow, protect, operate and finance your business. Our polycentric and purpose-driven approach, together with our commitment to inclusion, diversity, equity and ESG, ensures we challenge the status quo to stay focused on what matters most to you. www.dentons.com